SeaStar Medical(ICU) - 2025 Q4 - Annual Results

Adds top-rated children's hospitals to QUELIMMUNE™ pediatric AKI customer base Completes enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeds 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advances pipeline indications with initiation of cardio-renal clinical trial Exhibit 99.1 SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Webcast today at 4:30 pm Eastern Time DENVER, CO., March 25, 2026 – ...